Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SHPH
Shuttle Pharmaceuticals Holdings, Inc.
|
-- | -- | -- | -- | -- |
|
JNJ
Johnson & Johnson
|
$23.8B | $2.76 | 7.18% | 79.14% | $209.29 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
OGEN
Oragenics, Inc.
|
-- | -- | -- | -- | $2.00 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
|
TOVX
Theriva Biologics, Inc.
|
-- | -$0.38 | -- | -94.42% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SHPH
Shuttle Pharmaceuticals Holdings, Inc.
|
$1.80 | -- | $19.8M | -- | $0.00 | 0% | -- |
|
JNJ
Johnson & Johnson
|
$207.78 | $209.29 | $500.6B | 20.05x | $1.30 | 2.47% | 5.47x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$4.75 | $0.85 | $598.6M | 7.98x | $0.80 | 0% | 9.23x |
|
OGEN
Oragenics, Inc.
|
$0.84 | $2.00 | $687.2K | -- | $0.00 | 0% | 0.53x |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
|
TOVX
Theriva Biologics, Inc.
|
$0.20 | $7.00 | $6.8M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SHPH
Shuttle Pharmaceuticals Holdings, Inc.
|
32.37% | 1.158 | 1.71% | 1.07x |
|
JNJ
Johnson & Johnson
|
36.62% | 0.235 | 10.26% | 0.71x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | 2.113 | 8.08% | 1.85x |
|
OGEN
Oragenics, Inc.
|
3.86% | -0.075 | 36.62% | 3.97x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
29.07% | -3.365 | 66.16% | 0.68x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SHPH
Shuttle Pharmaceuticals Holdings, Inc.
|
-$1K | -$2.3M | -449.76% | -697.07% | -- | -$2.6M |
|
JNJ
Johnson & Johnson
|
$16.7B | $7.1B | 20.94% | 33.27% | 29.64% | $8B |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
OGEN
Oragenics, Inc.
|
-- | -$3.1M | -311.49% | -509.23% | -- | -$3M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
-$28K | -$4.4M | -148.18% | -171.04% | -- | -$4.3M |
Johnson & Johnson has a net margin of -- compared to Shuttle Pharmaceuticals Holdings, Inc.'s net margin of 21.47%. Shuttle Pharmaceuticals Holdings, Inc.'s return on equity of -697.07% beat Johnson & Johnson's return on equity of 33.27%.
| Company | Gross Margin | Earnings Per Share | Invested Capital |
|---|---|---|---|
|
SHPH
Shuttle Pharmaceuticals Holdings, Inc.
|
-- | -$1.05 | $2.1M |
|
JNJ
Johnson & Johnson
|
69.72% | $2.12 | $125.1B |
Shuttle Pharmaceuticals Holdings, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Johnson & Johnson has an analysts' consensus of $209.29 which suggests that it could grow by 0.73%. Given that Johnson & Johnson has higher upside potential than Shuttle Pharmaceuticals Holdings, Inc., analysts believe Johnson & Johnson is more attractive than Shuttle Pharmaceuticals Holdings, Inc..
| Company | Buy Ratings | Hold Ratings | Sell Ratings |
|---|---|---|---|
|
SHPH
Shuttle Pharmaceuticals Holdings, Inc.
|
0 | 0 | 0 |
|
JNJ
Johnson & Johnson
|
9 | 11 | 0 |
Shuttle Pharmaceuticals Holdings, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.357, suggesting its less volatile than the S&P 500 by 64.296%.
Shuttle Pharmaceuticals Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 2.47% to investors and pays a quarterly dividend of $1.30 per share. Shuttle Pharmaceuticals Holdings, Inc. pays -- of its earnings as a dividend. Johnson & Johnson pays out 84.8% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
Shuttle Pharmaceuticals Holdings, Inc. quarterly revenues are --, which are smaller than Johnson & Johnson quarterly revenues of $24B. Shuttle Pharmaceuticals Holdings, Inc.'s net income of -$2.3M is lower than Johnson & Johnson's net income of $5.2B. Notably, Shuttle Pharmaceuticals Holdings, Inc.'s price-to-earnings ratio is -- while Johnson & Johnson's PE ratio is 20.05x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Shuttle Pharmaceuticals Holdings, Inc. is -- versus 5.47x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.
| Company | Price/Sales Ratio | Price/Earnings Ratio | Quarterly Revenue | Quarterly Net Income |
|---|---|---|---|---|
|
SHPH
Shuttle Pharmaceuticals Holdings, Inc.
|
-- | -- | -- | -$2.3M |
|
JNJ
Johnson & Johnson
|
5.47x | 20.05x | $24B | $5.2B |
NovaBay Pharmaceuticals, Inc. has a net margin of -- compared to Shuttle Pharmaceuticals Holdings, Inc.'s net margin of -255.85%. Shuttle Pharmaceuticals Holdings, Inc.'s return on equity of -697.07% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
| Company | Gross Margin | Earnings Per Share | Invested Capital |
|---|---|---|---|
|
SHPH
Shuttle Pharmaceuticals Holdings, Inc.
|
-- | -$1.05 | $2.1M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
8.06% | -$0.22 | $2.6M |
Shuttle Pharmaceuticals Holdings, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -82.11%. Given that NovaBay Pharmaceuticals, Inc. has higher upside potential than Shuttle Pharmaceuticals Holdings, Inc., analysts believe NovaBay Pharmaceuticals, Inc. is more attractive than Shuttle Pharmaceuticals Holdings, Inc..
| Company | Buy Ratings | Hold Ratings | Sell Ratings |
|---|---|---|---|
|
SHPH
Shuttle Pharmaceuticals Holdings, Inc.
|
0 | 0 | 0 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
1 | 0 | 0 |
Shuttle Pharmaceuticals Holdings, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.
Shuttle Pharmaceuticals Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Shuttle Pharmaceuticals Holdings, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
Shuttle Pharmaceuticals Holdings, Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Shuttle Pharmaceuticals Holdings, Inc.'s net income of -$2.3M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Shuttle Pharmaceuticals Holdings, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 7.98x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Shuttle Pharmaceuticals Holdings, Inc. is -- versus 9.23x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
| Company | Price/Sales Ratio | Price/Earnings Ratio | Quarterly Revenue | Quarterly Net Income |
|---|---|---|---|---|
|
SHPH
Shuttle Pharmaceuticals Holdings, Inc.
|
-- | -- | -- | -$2.3M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
9.23x | 7.98x | $521K | -$1.3M |
Oragenics, Inc. has a net margin of -- compared to Shuttle Pharmaceuticals Holdings, Inc.'s net margin of --. Shuttle Pharmaceuticals Holdings, Inc.'s return on equity of -697.07% beat Oragenics, Inc.'s return on equity of -509.23%.
| Company | Gross Margin | Earnings Per Share | Invested Capital |
|---|---|---|---|
|
SHPH
Shuttle Pharmaceuticals Holdings, Inc.
|
-- | -$1.05 | $2.1M |
|
OGEN
Oragenics, Inc.
|
-- | -$1.96 | $10.2M |
Shuttle Pharmaceuticals Holdings, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Oragenics, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 139.49%. Given that Oragenics, Inc. has higher upside potential than Shuttle Pharmaceuticals Holdings, Inc., analysts believe Oragenics, Inc. is more attractive than Shuttle Pharmaceuticals Holdings, Inc..
| Company | Buy Ratings | Hold Ratings | Sell Ratings |
|---|---|---|---|
|
SHPH
Shuttle Pharmaceuticals Holdings, Inc.
|
0 | 0 | 0 |
|
OGEN
Oragenics, Inc.
|
1 | 0 | 0 |
Shuttle Pharmaceuticals Holdings, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Oragenics, Inc. has a beta of 0.922, suggesting its less volatile than the S&P 500 by 7.781%.
Shuttle Pharmaceuticals Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Shuttle Pharmaceuticals Holdings, Inc. pays -- of its earnings as a dividend. Oragenics, Inc. pays out -- of its earnings as a dividend.
Shuttle Pharmaceuticals Holdings, Inc. quarterly revenues are --, which are smaller than Oragenics, Inc. quarterly revenues of --. Shuttle Pharmaceuticals Holdings, Inc.'s net income of -$2.3M is higher than Oragenics, Inc.'s net income of -$3.1M. Notably, Shuttle Pharmaceuticals Holdings, Inc.'s price-to-earnings ratio is -- while Oragenics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Shuttle Pharmaceuticals Holdings, Inc. is -- versus 0.53x for Oragenics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
| Company | Price/Sales Ratio | Price/Earnings Ratio | Quarterly Revenue | Quarterly Net Income |
|---|---|---|---|---|
|
SHPH
Shuttle Pharmaceuticals Holdings, Inc.
|
-- | -- | -- | -$2.3M |
|
OGEN
Oragenics, Inc.
|
0.53x | -- | -- | -$3.1M |
Palatin Technologies has a net margin of -- compared to Shuttle Pharmaceuticals Holdings, Inc.'s net margin of --. Shuttle Pharmaceuticals Holdings, Inc.'s return on equity of -697.07% beat Palatin Technologies's return on equity of --.
| Company | Gross Margin | Earnings Per Share | Invested Capital |
|---|---|---|---|
|
SHPH
Shuttle Pharmaceuticals Holdings, Inc.
|
-- | -$1.05 | $2.1M |
|
PTN
Palatin Technologies
|
-- | -- | -- |
Shuttle Pharmaceuticals Holdings, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Shuttle Pharmaceuticals Holdings, Inc., analysts believe Palatin Technologies is more attractive than Shuttle Pharmaceuticals Holdings, Inc..
| Company | Buy Ratings | Hold Ratings | Sell Ratings |
|---|---|---|---|
|
SHPH
Shuttle Pharmaceuticals Holdings, Inc.
|
0 | 0 | 0 |
|
PTN
Palatin Technologies
|
0 | 0 | 0 |
Shuttle Pharmaceuticals Holdings, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
Shuttle Pharmaceuticals Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Shuttle Pharmaceuticals Holdings, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
Shuttle Pharmaceuticals Holdings, Inc. quarterly revenues are --, which are larger than Palatin Technologies quarterly revenues of --. Shuttle Pharmaceuticals Holdings, Inc.'s net income of -$2.3M is higher than Palatin Technologies's net income of --. Notably, Shuttle Pharmaceuticals Holdings, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Shuttle Pharmaceuticals Holdings, Inc. is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
| Company | Price/Sales Ratio | Price/Earnings Ratio | Quarterly Revenue | Quarterly Net Income |
|---|---|---|---|---|
|
SHPH
Shuttle Pharmaceuticals Holdings, Inc.
|
-- | -- | -- | -$2.3M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- |
Theriva Biologics, Inc. has a net margin of -- compared to Shuttle Pharmaceuticals Holdings, Inc.'s net margin of --. Shuttle Pharmaceuticals Holdings, Inc.'s return on equity of -697.07% beat Theriva Biologics, Inc.'s return on equity of -171.04%.
| Company | Gross Margin | Earnings Per Share | Invested Capital |
|---|---|---|---|
|
SHPH
Shuttle Pharmaceuticals Holdings, Inc.
|
-- | -$1.05 | $2.1M |
|
TOVX
Theriva Biologics, Inc.
|
-- | -$0.45 | $9.5M |
Shuttle Pharmaceuticals Holdings, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3349.98%. Given that Theriva Biologics, Inc. has higher upside potential than Shuttle Pharmaceuticals Holdings, Inc., analysts believe Theriva Biologics, Inc. is more attractive than Shuttle Pharmaceuticals Holdings, Inc..
| Company | Buy Ratings | Hold Ratings | Sell Ratings |
|---|---|---|---|
|
SHPH
Shuttle Pharmaceuticals Holdings, Inc.
|
0 | 0 | 0 |
|
TOVX
Theriva Biologics, Inc.
|
1 | 1 | 0 |
Shuttle Pharmaceuticals Holdings, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.
Shuttle Pharmaceuticals Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Shuttle Pharmaceuticals Holdings, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.
Shuttle Pharmaceuticals Holdings, Inc. quarterly revenues are --, which are smaller than Theriva Biologics, Inc. quarterly revenues of --. Shuttle Pharmaceuticals Holdings, Inc.'s net income of -$2.3M is higher than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, Shuttle Pharmaceuticals Holdings, Inc.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Shuttle Pharmaceuticals Holdings, Inc. is -- versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
| Company | Price/Sales Ratio | Price/Earnings Ratio | Quarterly Revenue | Quarterly Net Income |
|---|---|---|---|---|
|
SHPH
Shuttle Pharmaceuticals Holdings, Inc.
|
-- | -- | -- | -$2.3M |
|
TOVX
Theriva Biologics, Inc.
|
0.33x | -- | -- | -$4.4M |
Signup to receive the latest stock alerts
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Market Cap: $4.6T
P/E Ratio: 64x
Market Cap: $4T
P/E Ratio: 37x
Market Cap: $3.8T
P/E Ratio: 39x
Hut 8 Corp. [HUT] is up 0.65% over the past day.
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.